SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Digital Turbine, Inc. is a mobile growth platform that offers solutions for advertisers, publishers, carriers, and device original equipment manufacturers (OEMs). The firm operates through the On Device Solutions (ODS) and App Growth Platform (AGP) segments. The ODS segment generates revenue from the delivery of mobile application media or content to end users with solutions for all participants in the mobile application ecosystem that want to connect with end users and consumers who hold the device. This includes mobile carriers and device OEMs that participate in the app economy, app publishers and developers, and brands and advertising agencies. The AGP segment provides platforms that allow mobile app publishers and developers to monetize their monthly active users via display, native, and video advertising. The company was founded on November 6, 1998 and is headquartered in Austin, TX.

Digital Turbine Inc

Digital Turbine is experiencing significant market interest following a strong quarterly earnings report that beat analyst expectations and featured positive forward-looking revenue guidance for fiscal year 2027. Community sentiment is currently driven by a mix of bullish optimism surrounding the company's AI-driven growth strategies and partnerships, contrasted by active debates among traders regarding the company's debt load and the potential for a short squeeze.

Zscaler, Inc. engages in the provision of a cloud-based internet security platform. It offers Zero Trust Exchange, Zscaler Client Connector, Zscaler Internet Access, Zscaler Private Access, Zscaler B2B, Zscaler Cloud Protection, and Zscaler Digital Experience. The company was founded by Jagtar Singh Chaudhry and K. Kailash in September 2007 and is headquartered in San Jose, CA.

Zscaler Inc

Zscaler shares plummeted following a fiscal third-quarter earnings report that featured a guidance miss, leading to concerns over decelerating growth and increased capital expenditure. The community is sharply divided between investors panicking over management's narrative and leadership changes, and those attempting to buy the dip, with many debating if the company's valuation still holds as growth slows.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is seeing significant volatility and increased interest driven by a combination of a technically oversold chart structure and speculative momentum regarding the company's Matrix-M adjuvant platform's potential use in emerging disease outbreaks. Community discourse is sharply divided between retail investors betting on a short squeeze or buyout potential and those frustrated by the company's leadership and persistent lack of clear communication regarding pipeline execution.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is seeing massive trading volume and parabolic price action as analysts rapidly hike price targets amid an AI-driven memory chip supply shortage. The community is deeply divided, with bulls pointing to the company's structural pivot into an essential AI infrastructure provider, while vocal bears argue the rapid surge has reached unsustainable, meme-like bubble territory.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Sellas Life Sciences is generating intense community buzz as investors anticipate the final data readout for its lead cancer therapy, GPS, while closely tracking the company's efforts to position the drug as a superior, non-toxic alternative to current maintenance therapies. Discussions are heavily focused on the clinical trial's 80th event trigger, potential institutional interest ahead of upcoming industry conferences, and the high-conviction belief that current price action is being influenced by warrant activity rather than fundamental weakness.

Redwire Corp. manufactures and supplies space equipment. It offers critical space solutions and reliability components for the next generation space economy with IP for solar power generation and in-space 3D printing and manufacturing. It assists its customers in solving challenges of future space missions. The company was founded in 2020 and is headquartered in Jacksonville, FL.

Redwire Corporation

Redwire Corp

Redwire Corp is experiencing significant upward momentum as investors flock to space infrastructure stocks, fueled by its strategic role in NASA projects and speculation surrounding the upcoming SpaceX IPO. The community is actively discussing a potential short squeeze, with many retail traders holding strong and sharing bullish sentiment despite warnings of potential volatility.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X ETF

Direxion Daily Semiconductor Bear 3X Shares

Investors are actively debating the sustainability of the semiconductor sector's parabolic rally, with many expressing deep frustration over aggressive profit-taking and the volatility of holding leveraged inverse products like SOXS. The community remains fixated on extreme valuations and potential signs of a market blow-off top, despite persistent institutional buying in key tech stocks that continues to squeeze bear positions.

Momentus, Inc. engages in the provision of in-space infrastructure services. It offers space transportation and in-orbit servicing. The company was founded by Mikhail Kokorich in 2017 and is headquartered in Santa Jose, CA.

Momentus Inc - Ordinary Shares - Class A

Momentus Inc. is seeing intense momentum as retail traders speculate on a potential sector-wide rally fueled by anticipation surrounding the upcoming SpaceX IPO. While community sentiment is heavily polarized between aggressive bullishness on the stock's short-float potential and skepticism regarding past capital raises and dilution concerns, the stock remains a focal point for momentum traders navigating high volatility.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is seeing intense retail speculation and aggressive buying as the semiconductor sector continues its parabolic climb, fueled by AI infrastructure hype. While bullish community members are pushing for higher price targets and dismissing pullback warnings, caution is mounting as some traders highlight the extreme overbought conditions, lack of fundamental divergence, and high risks associated with holding a 3x leveraged ETF during such volatile market conditions.

Groupon, Inc. engages in the global scaled two-sided marketplace that connects consumers to merchants. It operates through the North America and International geographical segments. The company was founded by Andrew D. Mason, Eric Paul Lefkofsky, and Bradley A. Keywell in October 2008 and is headquartered in Chicago, IL.

Groupon Inc

Groupon is experiencing significant upward momentum as investors highlight a textbook short squeeze setup characterized by extremely high short interest, a shrinking free float due to active buybacks, and significant dealer hedging activity around key strike prices. Community sentiment is overwhelmingly bullish, with traders drawing parallels to historic short squeezes and actively discussing the potential for a parabolic move as they aim to force institutional shorts to cover their positions.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$ITRM here’s a simple math: $7.2 billion spent to treat uUTIs in 2024. This treatment is dominated by $4-$20/dose drugs and only .2% of uUTIs end up in the hospital, so where’s all the money going? It’s for all these women that get repeat infections and they don’t respond to that first generic and then they end up in what’s called a treatment cascade  failure of multiple office visits, lab cultures,  a whole bunch of tests, different generics, and the money starts to add up. We ran the number several times and it’s over $2 billion per year You can save if you use ORLY at the first office visit for the women that are highly likely to not respond to the first generic prescribed. This is the same environment that GSK, who spent 600 million to develop bluejepa, will be in, although I like to look at bluejepa as more of a complementary versus direct competitor for a bunch of reasons I won’t discuss here. Any new drug in this space has to steal market share from $4GENERICS  from 1953.

Jordan

ALAS

Mr.Yoda

eskimo242

Sheymus8

ItisMe

StockTwits for iOS

Iterum Therapeutics Plc

 here’s a simple math: $7.2 billion spent to treat uUTIs in 2024. This treatment is dominated by $4-$20/dose drugs and only .2% of uUTIs end up in the hospital, so where’s all the money going? It’s for all these women that get repeat infections and they don’t respond to that first generic and then they end up in what’s called a treatment cascade  failure of multiple office visits, lab cultures,  a whole bunch of tests, different generics, and the money starts to add up. We ran the number several times and it’s over $2 billion per year You can save if you use ORLY at the first office visit for the women that are highly likely to not respond to the first generic prescribed. This is the same environment that GSK, who spent 600 million to develop bluejepa, will be in, although I like to look at bluejepa as more of a complementary versus direct competitor for a bunch of reasons I won’t discuss here. Any new drug in this space has to steal market share from $4GENERICS  from 1953.